New hope for rare cancers: drug combo targets BRAF mutation

NCT ID NCT05868629

Recruiting now Disease control Sponsor: Novartis Pharmaceuticals Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests a combination of two targeted drugs, dabrafenib and trametinib, in people with rare solid tumors that have a specific genetic change called BRAF V600E. The goal is to see how well the drugs shrink or control the tumors. The study includes both children (age 1 and older) and adults whose tumors cannot be removed by surgery or have spread to other parts of the body.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for RARE UNRESECTABLE OR METASTATIC BRAF V600E MUTATION-POSITIVE SOLID TUMORS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

hereditary sensory and autonomic neuropathy

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

RARE UNRESECTABLE OR METASTATIC BRAF V600E MUTATION-POSITIVE SOLID TUMORS

Contacts and locations

Locations

Duke Clinical Research Institute
RECRUITING

Durham, North Carolina, 27704, United States
El Paso Texas Oncology
RECRUITING

El Paso, Texas, 79902, United States
Johns Hopkins University
RECRUITING

Washington D.C., District of Columbia, 20016, United States
Lundquist Inst BioMed at Harbor
RECRUITING

Torrance, California, 90509-2910, United States
Oncology Hematology Care Inc
RECRUITING

Cincinnati, Ohio, 45242, United States
Rocky Mountain Cancer Centers
RECRUITING

Denver, Colorado, 80218, United States
Sarah Cannon Research Institute
RECRUITING

Nashville, Tennessee, 37203, United States
Texas Oncology San Antonio
RECRUITING

San Antonio, Texas, 78258, United States